# An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients

> **NCT00189930** · PHASE2 · COMPLETED · sponsor: **Bavarian Nordic** · enrollment: 77 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **BIOLOGICAL:** MVA-nef
- **BIOLOGICAL:** IMVAMUNE

## Key facts

- **NCT ID:** NCT00189930
- **Lead sponsor:** Bavarian Nordic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2012-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00189930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00189930, "An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00189930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*